Summary:
A phase III, 52-week, multinational, multicenter, randomized, double-blind, 2-arm parallel group study comparing efficacy, safety and tolerability of the fixed dose triple combination of beclomethasone dipropionate plus formoterol fumarate plus glycopyrronium bromide (CHF 5993) with the fixed dose dual combination of beclomethasone dipropionate plus formoterol fumarate (CHF 1535), both administered via pMDI in subjects with chronic obstructive pulmonary disease (COPD)
Qualified Participants Must:
• Have been diagnosed with COPD for at least 12 months prior
•
Have to be 40 years old and up
•
Current or ex-smoker who quit at least 6 months prior
•
Stable daily ihaled maintenance therapy for at least 3 months prior
Qualified Participants May Receive:
Participants will receive compensation for their time and travel.